REFERENCES
- Abe M., Kondo T., Xu H., Fairchild R. L. Interferon-gamma inducible protein (IP-10) expression is mediated by CD8+ T cells and is regulated by CD4+ T cells during the elicitation of contact hypersensitivity. J Invest Dermatol 1996; 107(3)360–366, [INFOTRIEVE], [CSA]
- Adams J. M., Harris A. W., Pinkert C. A., Corcoran L. M., Alexander W. S., Cory S., Palmiter R. D., Brinster R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318(6046)533–538, [INFOTRIEVE], [CSA], [CROSSREF]
- Ansel K. M., Cyster J. G. Chemokines in lymphopoiesis and lymphoid organ development. Curr. Opin. Immunol 2001; 13(2)172–179, [INFOTRIEVE], [CSA], [CROSSREF]
- Arbeit J. M., Munger K., Howley P. M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol 1994; 68(7)4358–4368, [INFOTRIEVE], [CSA]
- Armstrong T. D., Jaffee E. M. Cytokine modified tumor vaccines. Surg. Oncol. Clin. N. Am 2002; 11(3)681–696, [INFOTRIEVE], [CSA], [CROSSREF]
- Arnold J., de Boer E. C., O'Donnell M. A., Bohle A., Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother 2004; 27(2)116–123, [INFOTRIEVE], [CSA], [CROSSREF]
- Aslakson C. J., Miller F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52(6)1399–1405, [INFOTRIEVE], [CSA]
- Bach E. A., Aguet M., Schreiber R. D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol 1997; 15: 563–591, [INFOTRIEVE], [CSA], [CROSSREF]
- Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357(9255)539–545, [INFOTRIEVE], [CSA], [CROSSREF]
- Biragyn A., Ruffini P. A., Coscia M., Harvey L. K., Neelapu S. S., Baskar S., Wang J. M., Kwak L. W. Chemokine receptor-mediated delivery directs self‐tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004; 104(7)1961–1969, [INFOTRIEVE], [CSA], [CROSSREF]
- Boehm U., Klamp T., Groot M., Howard J. C. Cellular responses to interferon-gamma. Annu. Rev. Immunol 1997; 15: 749–795, [INFOTRIEVE], [CSA], [CROSSREF]
- Bour H., Peyron E., Gaucherand M., Garrigue J. L., Desvignes C., Kaiserlian D., Revillard J. P., Nicolas J. F. Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol 1995; 25(11)3006–3010, [INFOTRIEVE], [CSA]
- Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000; 19(21)2474–2488, [INFOTRIEVE], [CSA], [CROSSREF]
- Bratt A., Wilson W. J., Troyanovsky B., Aase K., Kessler R., Van Meir E. G., Holmgren L. Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 2002; 298(1)69–77, [INFOTRIEVE], [CSA], [CROSSREF]
- Bratt A., Birot O., Sinha I., Veitonmaki N., Aase K., Ernkvist M., Holmgren L. Angiomotin regulates endothelial cell-cell junctions and cell motility. J. Biol. Chem 2005; 280(41)34859–34869, [INFOTRIEVE], [CSA], [CROSSREF]
- Brigati C., Noonan D. M., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin. Exp. Metastasis 2002; 19(3)247–258, [INFOTRIEVE], [CSA], [CROSSREF]
- Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest 2002; 109(9)1139–1142, [INFOTRIEVE], [CSA], [CROSSREF]
- Bromberg J. F., Horvath C. M., Wen Z., Schreiber R. D., Darnell J. E., Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 1996; 93(15)7673–7678, [INFOTRIEVE], [CSA], [CROSSREF]
- Bromberg J. F., Wrzeszczynska M. H., Devgan G., Zhao Y., Pestell R. G., Albanese C., Darnell J. E., Jr. Stat3 as an oncogene. Cell 1999; 98(3)295–303, [INFOTRIEVE], [CSA], [CROSSREF]
- Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., Dalton W., Pardoll D., Wei S., Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol 2005; 174(7)3925–3931, [INFOTRIEVE], [CSA]
- Calvo A., Yokoyama Y., Smith L. E., Ali I., Shih S. C., Feldman A. L., Libutti S. K., Sundaram R., Green J. E. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int. J. Cancer 2002; 101(3)224–234, [INFOTRIEVE], [CSA], [CROSSREF]
- Campbell M. J., Carroll W., Kon S., Thielemans K., Rothbard J. B., Levy S., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol 1987; 139(8)2825–2833, [INFOTRIEVE], [CSA]
- Campbell M. J., Esserman L., Byars N. E., Allison A. C., Levy R. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int. Rev. Immunol 1989; 4(4)251–270, [INFOTRIEVE], [CSA]
- Campbell M. J., Esserman L., Byars N. E., Allison A. C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol 1990; 145(3)1029–1036, [INFOTRIEVE], [CSA]
- Campbell M. J., Esserman L., Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J. Immunol 1988; 141(9)3227–3233, [INFOTRIEVE], [CSA]
- Campoli M., Chang C. C., Oldford S. A., Edgecombe A. D., Drover S., Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 2004; 20: 105–125, [INFOTRIEVE], [CSA]
- Caspar C. B., Levy S., Levy R. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997; 90(9)3699–3706, [INFOTRIEVE], [CSA]
- Catlett-Falcone R., Landowski T. H., Oshiro M. M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J. L., Nunez G., Dalton W. S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10(1)105–115, [INFOTRIEVE], [CSA], [CROSSREF]
- Cerny T., Borisch B., Introna M., Johnson P., Rose A. L. Mechanism of action of rituximab. Anticancer Drugs 2002; 13(Suppl 2)S3–10, [INFOTRIEVE], [CSA]
- Chang C. J., Tai K. F., Roffler S., Hwang L. H. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J. Immunol 2004; 173(10)6025–6032, [INFOTRIEVE], [CSA]
- Chen L. K., Tourvieille B., Burns G. F., Bach F. H., Mathieu-Mahul D., Sasportes M., Bensussan A. Interferon: a cytotoxic T lymphocyte differentiation signal. Eur. J. Immunol 1986; 16(7)767–770, [INFOTRIEVE], [CSA]
- Cheng F., Wang H. W., Cuenca A., Huang M., Ghansah T., Brayer J., Kerr W. G., Takeda K., Akira S., Schoenberger S. P., Yu H., Jove R., Sotomayor E. M. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19(3)425–436, [INFOTRIEVE], [CSA], [CROSSREF]
- Chin Y. E., Kitagawa M., Su W. C., You Z. H., Iwamoto Y., Fu X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272(5262)719–722, [INFOTRIEVE], [CSA]
- Cohen C. J., Zheng Z., Bray R., Zhao Y., Sherman L. A., Rosenberg S. A., Morgan R. A. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol 2005; 175(9)5799–5808, [INFOTRIEVE], [CSA]
- Collart M. A., Belin D., Vassalli J. D., de Kossodo S., Vassalli P. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med 1986; 164(6)2113–2118, [INFOTRIEVE], [CSA], [CROSSREF]
- Couch M., Saunders J. K., O'Malley B. W., Jr., Pardoll D., Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 2003; 113(3)552–556, [INFOTRIEVE], [CSA], [CROSSREF]
- Coukos G., Conejo-Garcia J. R., Roden R. B., Wu T. C. Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther 2005; 5(9)1193–1210, [INFOTRIEVE], [CSA], [CROSSREF]
- Coussens L. M., Tinkle C. L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103(3)481–490, [INFOTRIEVE], [CSA], [CROSSREF]
- Coussens L. M., Werb Z. Inflammation and cancer. Nature 2002; 420(6917)860–867, [INFOTRIEVE], [CSA], [CROSSREF]
- Cozar J. M., Canton J., Tallada M., Concha A., Cabrera T., Garrido F., Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol. Immunother 2005; 54(9)858–866, [INFOTRIEVE], [CSA], [CROSSREF]
- Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med 2004; 10(9)942–949, [INFOTRIEVE], [CSA], [CROSSREF]
- Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L. A., Chu N. R., Hanahan D. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 2005; 65(5)2018–2025, [INFOTRIEVE], [CSA], [CROSSREF]
- Daniel D., Meyer-Morse N., Bergsland E. K., Dehne K., Coussens L. M., Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med 2003; 197(8)1017–1028, [INFOTRIEVE], [CSA], [CROSSREF]
- Darnell J. E., Jr. STATs and gene regulation. Science 1997; 277(5332)1630–1635, [INFOTRIEVE], [CSA], [CROSSREF]
- Davis T. A., Grillo-Lopez A. J., White C. A., McLaughlin P., Czuczman M. S., Link B. K., Maloney D. G., Weaver R. L., Rosenberg J., Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol 2000; 18(17)3135–3143, [INFOTRIEVE], [CSA]
- Davis T. A., Maloney D. G., Czerwinski D. K., Liles T. M., Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92(4)1184–1190, [INFOTRIEVE], [CSA]
- Dilulio N. A., Engeman T., Armstrong D., Tannenbaum C., Hamilton T. A., Fairchild R. L. Groalpha-mediated recruitment of neutrophils is required for elicitation of contact hypersensitivity. Eur. J. Immunol 1999; 29(11)3485–3495, [INFOTRIEVE], [CSA], [CROSSREF]
- Djeu J. Y., Stocks N., Zoon K., Stanton G. J., Timonen T., Herberman R. B. Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J. Exp. Med 1982; 156(4)1222–1234, [INFOTRIEVE], [CSA], [CROSSREF]
- Dobrzanski M. J., Reome J. B., Dutton R. W. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol 2001; 98(1)70–84, [INFOTRIEVE], [CSA], [CROSSREF]
- Dominiecki M. E., Beatty G. L., Pan Z. K., Neeson P., Paterson Y. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol. Immunother 2005; 54(5)477–488, [INFOTRIEVE], [CSA], [CROSSREF]
- Dunn G. P., Old L. J., Schreiber R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004a; 21(2)137–148, [INFOTRIEVE], [CSA]
- Dunn G. P., Old L. J., Schreiber R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol 2004b; 22: 329–360, [INFOTRIEVE], [CSA]
- Ebbinghaus C., Ronca R., Kaspar M., Grabulovski D., Berndt A., Kosmehl H., Zardi L., Neri D. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 2005; 116(2)304–313, [INFOTRIEVE], [CSA], [CROSSREF]
- Engeman T., Gorbachev A. V., Kish D. D., Fairchild R. L. The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites. J. Leukoc. Biol 2004; 76(5)941–949, [INFOTRIEVE], [CSA], [CROSSREF]
- Epling-Burnette P. K., Liu J. H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J. M., Yang-Yen H. F., Karras J., Jove R., Loughran T. P., Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest 2001; 107(3)351–362, [INFOTRIEVE], [CSA]
- Farber J. M. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol 1997; 61(3)246–257, [INFOTRIEVE], [CSA]
- Farrar M. A., Schreiber R. D. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol 1993; 11: 571–611, [INFOTRIEVE], [CSA], [CROSSREF]
- Feldman A. L., Alexander H. R., Hewitt S. M., Lorang D., Thiruvathukal C. E., Turner E. M., Libutti S. K. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst 2001; 93(13)1014–1020, [INFOTRIEVE], [CSA], [CROSSREF]
- Gattinoni L., Finkelstein S. E., Klebanoff C. A., Antony P. A., Palmer D. C., Spiess P. J., Hwang L. N., Yu Z., Wrzesinski C., Heimann D. M., Surh C. D., Rosenberg S. A., Restifo N. P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med 2005; 202(7)907–912, [INFOTRIEVE], [CSA], [CROSSREF]
- Gee M. S., Koch C. J., Evans S. M., Jenkins W. T., Pletcher C. H., Jr., Moore J. S., Koblish H. K., Lee J., Lord E. M., Trinchieri G., Lee W. M. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999; 59(19)4882–4889, [INFOTRIEVE], [CSA]
- Gee M. S., Procopio W. N., Makonnen S., Feldman M. D., Yeilding N. M., Lee W. M. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol 2003; 162(1)183–193, [INFOTRIEVE], [CSA]
- Golgher D., Jones E., Powrie F., Elliott T., Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol 2002; 32(11)3267–3275, [INFOTRIEVE], [CSA], [CROSSREF]
- Gough M., Crittenden M., Thanarajasingam U., Sanchez-Perez L., Thompson J., Jevremovic D., Vile R. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J. Immunol 2005; 174(9)5766–5773, [INFOTRIEVE], [CSA]
- Greenlund A. C., Morales M. O., Viviano B. L., Yan H., Krolewski J., Schreiber R. D. Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 1995; 2(6)677–687, [INFOTRIEVE], [CSA], [CROSSREF]
- Gunn G. R., Zubair A., Peters C., Pan Z. K., Wu T. C., Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol 2001; 167(11)6471–6479, [INFOTRIEVE], [CSA]
- Guy C. T., Cardiff R. D., Muller W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol 1992a; 12(3)954–961, [INFOTRIEVE], [CSA]
- Guy C. T., Webster M. A., Schaller M., Parsons T. J., Cardiff R. D., Muller W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992b; 89(22)10578–10582, [INFOTRIEVE], [CSA], [CROSSREF]
- Hamano Y., Zeisberg M., Sugimoto H., Lively J. C., Maeshima Y., Yang C., Hynes R. O., Werb Z., Sudhakar A., Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003; 3(6)589–601, [INFOTRIEVE], [CSA], [CROSSREF]
- Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3)353–364, [INFOTRIEVE], [CSA], [CROSSREF]
- Hemmann U., Gerhartz C., Heesel B., Sasse J., Kurapkat G., Grotzinger J., Wollmer A., Zhong Z., Darnell J. E., Jr., Graeve L., Heinrich P. C., Horn F. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem 1996; 271(22)12999–13007, [INFOTRIEVE], [CSA], [CROSSREF]
- Hinrichs C. S., Palmer D. C., Rosenberg S. A., Restifo N. P. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J. Immunother 2005; 28(6)517–524, [INFOTRIEVE], [CSA], [CROSSREF]
- Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422)1994–1998, [INFOTRIEVE], [CSA], [CROSSREF]
- Homey B., Alenius H., Muller A., Soto H., Bowman E. P., Yuan W., McEvoy L., Lauerma A. I., Assmann T., Bunemann E., Lehto M., Wolff H., Yen D., Marxhausen H., To W., Sedgwick J., Ruzicka T., Lehmann P., Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med 2002; 8(2)157–165, [INFOTRIEVE], [CSA], [CROSSREF]
- Horvath C. M., Wen Z., Darnell J. E., Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 1995; 9(8)984–994, [INFOTRIEVE], [CSA]
- Hsu F. J., Caspar C. B., Czerwinski D., Kwak L. W., Liles T. M., Syrengelas A., Taidi-Laskowski B., Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997; 89(9)3129–3135, [INFOTRIEVE], [CSA]
- Huang J., Khong H. T., Dudley M. E., El-Gamil M., Li Y. F., Rosenberg S. A., Robbins P. F. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother 2005; 28(3)258–267, [INFOTRIEVE], [CSA], [CROSSREF]
- Hussain S. F., Paterson Y. CD4 + CD25+regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J. Immunother 2004; 27(5)339–346, [INFOTRIEVE], [CSA], [CROSSREF]
- Hussein M. R. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br. J. Dermatol 2005; 153(1)18–21, [INFOTRIEVE], [CSA], [CROSSREF]
- Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med 2001; 194(6)847–853, [INFOTRIEVE], [CSA], [CROSSREF]
- Ishida Y., Kondo T., Takayasu T., Iwakura Y., Mukaida N. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J. Immunol 2004; 172(3)1848–1855, [INFOTRIEVE], [CSA]
- Itoh T., Storkus W. J., Gorelik E., Lotze M. T. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J. Immunol 1994; 153(3)1202–1215, [INFOTRIEVE], [CSA]
- Janeway C. A., Travers P., Walport M., Shlomchik M. J. Adaptive Immunity to infection. Immunobiology. Garland Science Publishing, C. A. Janeway, P. Travers, M. Walport, M. J. Shlomchik, 2005; 435–436
- Jia Z. C., Zou L. Y., Ni B., Wan Y., Zhou W., Lv Y. B., Geng M., Wu Y. Z. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Cancer Immunol. Immunother 2005; 54(5)446–452, [INFOTRIEVE], [CSA], [CROSSREF]
- Joncker N. T., Marloie M. A., Chernysheva A., Lonchay C., Cuff S., Klijanienko J., Sigal-Zafrani B., Vincent-Salomon A., Sastre X., Lantz O. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int. J. Cancer 2005; 118(5)1205–1214, [CSA], [CROSSREF]
- Kageshita T., Ishihara T., Campoli M., Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65(5)419–428, [INFOTRIEVE], [CSA], [CROSSREF]
- Kalish R. S., Johnson K. L. Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J. Immunol 1990; 145(11)3706–3713, [INFOTRIEVE], [CSA]
- Kaminska B., Wesolowska A., Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim. Pol 2005; 52(2)329–337, [INFOTRIEVE], [CSA]
- Kaminski M. S., Kitamura K., Maloney D. G., Campbell M. J., Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol 1986; 136(3)1123–1130, [INFOTRIEVE], [CSA]
- Kaminski M. S., Kitamura K., Maloney D. G., Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol 1987; 138(4)1289–1296, [INFOTRIEVE], [CSA]
- Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95(13)7556–61, [INFOTRIEVE], [CSA], [CROSSREF]
- Khong H. T., Wang Q. J., Rosenberg S. A. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother 2004; 27(3)184–190, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362(6423)841–844, [INFOTRIEVE], [CSA], [CROSSREF]
- Kunkel E. J., Butcher E. C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16(1)1–4, [INFOTRIEVE], [CSA], [CROSSREF]
- Kunz M., Toksoy A., Goebeler M., Engelhardt E., Brocker E., Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J. Pathol 1999; 189(4)552–558, [INFOTRIEVE], [CSA], [CROSSREF]
- Kwak L. W., Young H. A., Pennington R. W., Weeks S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 1996; 93(20)10972–10977, [INFOTRIEVE], [CSA], [CROSSREF]
- Lally K. M., Mocellin S., Ohnmacht G. A., Nielsen M. B., Bettinotti M., Panelli M. C., Monsurro V., Marincola F. M. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 2001; 93(6)841–847, [INFOTRIEVE], [CSA], [CROSSREF]
- Lamikanra A., Pan Z. K., Isaacs S. N., Wu T. C., Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J. Virol 2001; 75(20)9654–9664, [INFOTRIEVE], [CSA], [CROSSREF]
- Levy D. E., Darnell J. E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol 2002; 3(9)651–662, [INFOTRIEVE], [CSA], [CROSSREF]
- Li Y., Wang M. N., Li H., King K. D., Bassi R., Sun H., Santiago A., Hooper A. T., Bohlen P., Hicklin D. J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med 2002; 195(12)1575–1584, [INFOTRIEVE], [CSA], [CROSSREF]
- Lin K. Y., Guarnieri F. G., Staveley-O'Carroll K. F., Levitsky H. I., August J. T., Pardoll D. M., Wu T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56(1)21–26, [INFOTRIEVE], [CSA]
- Liu K., Caldwell S. A., Abrams S. I. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 2005; 65(10)4376–4388, [INFOTRIEVE], [CSA], [CROSSREF]
- Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol 2002; 169(5)2756–2761, [INFOTRIEVE], [CSA]
- Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., Chaitchik S., Keydar I., Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59(18)4681–4687, [INFOTRIEVE], [CSA]
- Lugade A. A., Moran J. P., Gerber S. A., Rose R. C., Frelinger J. G., Lord E. M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol 2005; 174(12)7516–7523, [INFOTRIEVE], [CSA]
- Maloney D. G. Mechanism of action of rituximab. Anticancer Drugs 2001; 12(Suppl 2)S1–4, [INFOTRIEVE], [CSA]
- Maraskovsky E., Chen W. F., Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J. Immunol 1989; 143(4)1210–1214, [INFOTRIEVE], [CSA]
- Maric M., Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res 1999; 59(21)5549–5553, [INFOTRIEVE], [CSA]
- Meeker T., Lowder J., Cleary M. L., Stewart S., Warnke R., Sklar J., Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med 1985; 312(26)1658–1665, [INFOTRIEVE], [CSA]
- Meissner M., Reichert T. E., Kunkel M., Gooding W., Whiteside T. L., Ferrone S., Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res 2005; 11(7)2552–2560, [INFOTRIEVE], [CSA], [CROSSREF]
- Meziane el K., Bhattacharyya T., Armstrong A. C., Qian C., Hawkins R. E., Stern P. L., Dermime S. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 2004; 111(6)910–920, [INFOTRIEVE], [CSA], [CROSSREF]
- Mule J. J., Custer M., Averbook B., Yang J. C., Weber J. S., Goeddel D. V., Rosenberg S. A., Schall T. J. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther 1996; 7(13)1545–1553, [INFOTRIEVE], [CSA]
- Nair S., Boczkowski D., Moeller B., Dewhirst M., Vieweg J., Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003; 102(3)964–971, [INFOTRIEVE], [CSA], [CROSSREF]
- Nathan C. F., Hibbs J. B., Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol 1991; 3(1)65–70, [INFOTRIEVE], [CSA], [CROSSREF]
- Neelapu S. S., Gause B. L., Nikcevich D. A., Schuster S. J., Winter J., Gockerman J. P., Loughran T., Jr., Takeshita K., Inghirami G., McGaughey D., Watson T. M., Snow S., Kubovic P., Ferraro M., Jones E., Jaffe E. S., Schwartzentruber D. J., Danforth D., Sherry R., Kass E., Van Waes C., Reynolds C. W., Kwak L. J. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin. Lymphoma 2005; 6(1)61–64, [INFOTRIEVE], [CSA]
- Negus R. P., Stamp G. W., Hadley J., Balkwill F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol 1997; 150(5)1723–1734, [INFOTRIEVE], [CSA]
- Niethammer A. G., Xiang R., Becker J. C., Wodrich H., Pertl U., Karsten G., Eliceiri B. P., Reisfeld R. A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med 2002; 8(12)1369–1375, [INFOTRIEVE], [CSA], [CROSSREF]
- Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res 2001; 7(2)285–289, [INFOTRIEVE], [CSA]
- Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59(13)3128–3133, [INFOTRIEVE], [CSA]
- Palmer D. C., Balasubramaniam S., Hanada K., Wrzesinski C., Yu Z., Farid S., Theoret M. R., Hwang L. N., Klebanoff C. A., Gattinoni L., Goldstein A. L., Yang J. C., Restifo N. P. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol 2004; 173(12)7209–7216, [INFOTRIEVE], [CSA]
- Pamer E. G. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol 2004; 4(10)812–823, [INFOTRIEVE], [CSA], [CROSSREF]
- Pan Z. K., Weiskirch L. M., Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 1999; 59(20)5264–5269, [INFOTRIEVE], [CSA]
- Paterson Y., Maciag P. C. Listeria-based vaccines for cancer treatment. Curr. Opin. Mol. Ther 2005; 7(5)454–460, [INFOTRIEVE], [CSA]
- Pertl U., Luster A. D., Varki N. M., Homann D., Gaedicke G., Reisfeld R. A., Lode H. N. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol 2001; 166(11)6944–6951, [INFOTRIEVE], [CSA]
- Piccirillo C. A., Shevach E. M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol 2004; 16(2)81–88, [INFOTRIEVE], [CSA], [CROSSREF]
- Piguet P. F., Grau G. E., Hauser C., Vassalli P. Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J. Exp. Med 1991; 173(3)673–679, [INFOTRIEVE], [CSA], [CROSSREF]
- Pollard J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004; 4(1)71–78, [INFOTRIEVE], [CSA], [CROSSREF]
- Porter D. L., June C. H. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: ‘T’ it up!. Bone Marrow Transplant 2005; 35(10)935–942, [INFOTRIEVE], [CSA], [CROSSREF]
- Qing Y., Stark G. R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem 2004; 279(40)41679–41685, [INFOTRIEVE], [CSA], [CROSSREF]
- Rapoport A. P., Stadtmauer E. A., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E., Zheng Z., Westphal S., Mair R., Chi N., Ratterree B., Pochran M. F., Natt S., Hinkle J., Sickles C., Sohal A., Ruehle K., Lynch C., Zhang L., Porter D. L., Luger S., Guo C., Fang H. B., Blackwelder W., Hankey K., Mann D., Edelman R., Frasch C., Levine B. L., Cross A., June C. H. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med 2005; 11(11)1230–1237, [INFOTRIEVE], [CSA], [CROSSREF]
- Reilly R. T., Machiels J. P., Emens L. A., Jaffee E. M. Cytokine gene-modified cell-based cancer vaccines. Meth. Mol. Med 2002; 69: 233–257, [CSA]
- Reiss Y., Proudfoot A. E., Power C. A., Campbell J. J., Butcher E. C. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med 2001; 194(10)1541–1547, [INFOTRIEVE], [CSA], [CROSSREF]
- Ribas A., Glaspy J. A., Lee Y., Dissette V. B., Seja E., Vu H. T., Tchekmedyian N. S., Oseguera D., Comin-Anduix B., Wargo J. A., Amarnani S. N., McBride W. H., Economou J. S., Butterfield L. H. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother 2004; 27(5)354–367, [INFOTRIEVE], [CSA], [CROSSREF]
- Rosa F. M., Cochet M. M., Fellous M. Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation?. Interferon 1986; 7: 47–87, [INFOTRIEVE], [CSA]
- Rovero S., Amici A., Carlo E. D., Bei R., Nanni P., Quaglino E., Porcedda P., Boggio K., Smorlesi A., Lollini P. L., Landuzzi L., Colombo M. P., Giovarelli M., Musiani P., Forni G. DNA “vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice”. J. Immunol 2000; 165(9)5133–5142, [INFOTRIEVE], [CSA]
- Ruffini P. A., Biragyn A., Coscia M., Harvey L. K., Cha S. C., Bogen B., Kwak L. W. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J. Leukoc. Biol 2004; 76(1)77–85, [INFOTRIEVE], [CSA], [CROSSREF]
- Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol 2005; 6(4)345–352, [INFOTRIEVE], [CSA], [CROSSREF]
- Saleh F., Renno W., Klepacek I., Ibrahim G., Dashti H., Asfar S., Behbehani A., Al-Sayer H., Dashti A., Kerry C. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Curr. Pharm. Des 2005; 11(27)3531–3543, [INFOTRIEVE], [CSA], [CROSSREF]
- Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401(6754)708–712, [INFOTRIEVE], [CSA], [CROSSREF]
- Sallusto F., Lenig D., Mackay C. R., Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med 1998; 187(6)875–883, [INFOTRIEVE], [CSA], [CROSSREF]
- Sallusto F., Mackay C. R. Chemoattractants and their receptors in homeostasis and inflammation. Curr. Opin. Immunol 2004; 16(6)724–731, [INFOTRIEVE], [CSA], [CROSSREF]
- Sallusto F., Mackay C. R., Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol 2000; 18: 593–620, [INFOTRIEVE], [CSA], [CROSSREF]
- Sanchez-Perez L., Kottke T., Diaz R. M., Ahmed A., Thompson J., Chong H., Melcher A., Holmen S., Daniels G., Vile R. G. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 2005; 65(5)2009–2017, [INFOTRIEVE], [CSA], [CROSSREF]
- Sano S., Itami S., Takeda K., Tarutani M., Yamaguchi Y., Miura H., Yoshikawa K., Akira S., Takeda J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo. J 1999; 18(17)4657–4668, [INFOTRIEVE], [CSA], [CROSSREF]
- Sauer M. G., Ericson M. E., Weigel B. J., Herron M. J., Panoskaltsis-Mortari A., Kren B. T., Levine B. L., Serody J. S., June C. H., Taylor P. A., Blazar B. R. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res 2004; 64(11)3914–3921, [INFOTRIEVE], [CSA], [CROSSREF]
- Scheffer S. R., Nave H., Korangy F., Schlote K., Pabst R., Jaffee E. M., Manns M. P., Greten T. F. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 2003; 103(2)205–211, [INFOTRIEVE], [CSA], [CROSSREF]
- Schindler C., Darnell J. E., Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem 1995; 64: 621–651, [INFOTRIEVE], [CSA], [CROSSREF]
- Schreiber R. D., Farrar M. A. The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol Jpn 1993; 28(Suppl. 4)88–94, discussion 95–96[INFOTRIEVE], [CSA]
- Seidel H. M., Milocco L. H., Lamb P., Darnell J. E., Jr., Stein R. B., Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 1995; 92(7)3041–3045, [INFOTRIEVE], [CSA], [CROSSREF]
- Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2005; 16(1)53–65, [INFOTRIEVE], [CSA], [CROSSREF]
- Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., Zanovello P., Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother 2004; 53(2)64–72, [INFOTRIEVE], [CSA], [CROSSREF]
- Sharma S., Stolina M., Zhu L., Lin Y., Batra R., Huang M., Strieter R., Dubinett S. M. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001; 61(17)6406–12, [INFOTRIEVE], [CSA]
- Shi W., Teschendorf C., Muzyczka N., Siemann D. W. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 2002; 9(6)513–521, [INFOTRIEVE], [CSA], [CROSSREF]
- Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol 1999; 163(10)5211–5218, [INFOTRIEVE], [CSA]
- Singh R., Dominiecki M. E., Jaffee E. M., Paterson Y. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol 2005; 175(6)3663–3673, [INFOTRIEVE], [CSA]
- Sinibaldi D., Wharton W., Turkson J., Bowman T., Pledger W. J., Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000; 19(48)5419–5427, [INFOTRIEVE], [CSA]
- Song W., Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 2005; 65(13)5958–5964, [INFOTRIEVE], [CSA], [CROSSREF]
- Spiess P. J., Yang J. C., Rosenberg S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst 1987; 79(5)1067–1075, [INFOTRIEVE], [CSA]
- Spiotto M. T., Fu Y. X., Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol 2003a; 15(6)725–730, [INFOTRIEVE], [CSA], [CROSSREF]
- Spiotto M. T., Reth M. A., Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc. Natl. Acad. Sci. USA 2003b; 100(9)5425–5430, [INFOTRIEVE], [CSA], [CROSSREF]
- Spiotto M. T., Rowley D. A., Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med 2004; 10(3)294–298, [INFOTRIEVE], [CSA], [CROSSREF]
- Spiotto M. T., Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 2005; 5: 8, [INFOTRIEVE], [CSA]
- Spiotto M. T., Yu P., Rowley D. A., Nishimura M. I., Meredith S. C., Gajewski T. F., Fu Y. X., Schreiber H. Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17(6)737–747, [INFOTRIEVE], [CSA], [CROSSREF]
- Stevens T., Rosenberg R., Aird W., Quertermous T., Johnson F. L., Garcia J. G., Hebbel R. P., Tuder R. M., Garfinkel S. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am. J. Physiol. Cell. Physiol 2001; 281(5)C1422–1433, [INFOTRIEVE], [CSA]
- Sun H., Kundu N., Dorsey R., Jackson M. J., Fulton A. M. Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. J. Immunother 2001; 24(2)138–143, [INFOTRIEVE], [CSA], [CROSSREF]
- Sutmuller R. P., van Duivenvoorde L. M., van Elsas A., Schumacher T. N., Wildenberg M. E., Allison J. P., Toes R. E., Offringa R., Melief C. J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med 2001; 194(6)823–832, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang H. L., Cyster J. G. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 1999; 284(5415)819–822, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang K. F., Tan S. Y., Chan S. H., Chong S. M., Loh K. S., Tan L. K., Hu H. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum. Pathol 2001; 32(1)42–49, [INFOTRIEVE], [CSA], [CROSSREF]
- Timmerman J. M., Caspar C. B., Lambert S. L., Syrengelas A. D., Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001; 97(5)1370–1377, [INFOTRIEVE], [CSA], [CROSSREF]
- Timmerman J. M., Czerwinski D. K., Davis T. A., Hsu F. J., Benike C., Hao Z. M., Taidi B., Rajapaksa R., Caspar C. B., Okada C. Y., van Beckhoven A., Liles T. M., Engleman E. G., Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99(5)1517–1526, [INFOTRIEVE], [CSA], [CROSSREF]
- Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998; 17(1–2)269–278, [INFOTRIEVE], [CSA]
- Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell. Biol 2001; 152(6)1247–1254, [INFOTRIEVE], [CSA], [CROSSREF]
- Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., Donato F., Wang X., Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res 2005; 11(1)67–72, [INFOTRIEVE], [CSA]
- Wada S., Tsunoda T., Baba T., Primus F. J., Kuwano H., Shibuya M., Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005; 65(11)4939–4946, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med 2004; 10(1)48–54, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang Z., Margulies L., Hicklin D. J., Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 1996; 47(5)382–390, [INFOTRIEVE], [CSA]
- Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., Curiel T., Lange A., Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65(12)5020–5026, [INFOTRIEVE], [CSA], [CROSSREF]
- Whiteside T. L., Stanson J., Shurin M. R., Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J. Immunol 2004; 173(3)1526–1534, [INFOTRIEVE], [CSA]
- Wiederkehr-Adam M., Ernst P., Muller K., Bieck E., Gombert F. O., Ottl J., Graff P., Grossmuller F., Heim M. H. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem 2003; 278(18)16117–16128, [INFOTRIEVE], [CSA], [CROSSREF]
- Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61(12)4766–4772, [INFOTRIEVE], [CSA]
- Wu M., Fang H., Hwang S. T. Cutting edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells. J. Immunol 2001a; 167(9)4791–4795, [INFOTRIEVE], [CSA]
- Wu R. S., Kobie J. J., Besselsen D. G., Fong T. C., Mack V. D., McEarchern J. A., Akporiaye E. T. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother 2001b; 50(5)229–240, [INFOTRIEVE], [CSA], [CROSSREF]
- Xu H., DiIulio N. A., Fairchild R. L. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J. Exp. Med 1996; 183(3)1001–1012, [INFOTRIEVE], [CSA], [CROSSREF]
- Yamshchikov G. V., Mullins D. W., Chang C. C., Ogino T., Thompson L., Presley J., Galavotti H., Aquila W., Deacon D., Ross W., Patterson J. W., Engelhard V. H., Ferrone S., Slingluff C. L., Jr. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol 2005; 174(11)6863–6871, [INFOTRIEVE], [CSA]
- Yang Y., Huang C. T., Huang X., Pardoll D. M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol 2004; 5(5)508–515, [INFOTRIEVE], [CSA], [CROSSREF]
- Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002; 99(25)16168–16173, [INFOTRIEVE], [CSA], [CROSSREF]
- Yoong K. F., Afford S. C., Jones R., Aujla P., Qin S., Price K., Hubscher S. G., Adams D. H. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999; 30(1)100–111, [INFOTRIEVE], [CSA], [CROSSREF]
- Yu P., Spiotto M. T., Lee Y., Schreiber H., Fu Y. X. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med 2003; 197(8)985–995, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang Q., Jang T. L., Yang X., Park I., Meyer R. E., Kundu S., Pins M., Javonovic B., Kuzel T., Kim S. J., Van Parijs L., Smith N., Wong L., Greenberg N. M., Guo Y., Lee C. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8(+) T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 2005a; 66(3)235–247, [CSA], [CROSSREF]
- Zhang Q., Yang X., Pins M., Javonovic B., Kuzel T., Kim S. J., Parijs L. V., Greenberg N. M., Liu V., Guo Y., Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005b; 65(5)1761–1769, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang T., Somasundaram R., Berencsi K., Caputo L., Rani P., Guerry D., Furth E., Rollins B. J., Putt M., Gimotty P., Swoboda R., Herlyn M., Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J. Immunol 2005c; 174(9)5856–5863, [INFOTRIEVE], [CSA]
- Zhou G., Lu Z., McCadden J. D., Levitsky H. I., Marson A. L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med 2004; 200(12)1581–1592, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhou J., Dudley M. E., Rosenberg S. A., Robbins P. F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother 2005a; 28(1)53–62, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhou H., Luo Y., Mizutani M., Mizutani N., Reisfeld R. A., Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005b; 106(6)2026–2032, [INFOTRIEVE], [CSA], [CROSSREF]